- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
New Medicare Advantage Entrants Increase Consumer Options
Although a new report from The Commonwealth Fund raised concerns about the competition of Medicare Advantage (MA) programs available across the country, a new analysis from Avalere Health found that there has been a growing number of MA plan options for consumers.
Although a new report from The Commonwealth Fund raised concerns about the competition of Medicare Advantage (MA) programs available across the country, a new analysis from Avalere Health found that there has been a growing number of MA plan options for consumers.
Between 2012 and 2015, 28 organizations entered the MA market and currently offer plans to beneficiaries, with a total of 104 new plan options available in 24 states.
“As the baby boomers become Medicare-eligible, organizations across the healthcare landscape are stepping up to compete,” Dan Mendelson, CEO at Avalere, said in a statement. “In particular, health systems are playing an even larger role in the Medicare Advantage program, further blurring the lines between providers and payers.”
These new entrants to the market include established commercial plans, major health systems, and provider groups that have become health plans. Provider-owned plans represent more than half (54%) of the new MA entrants.
“In addition to Medicare Advantage, providers are becoming payers to compete on exchanges and serve employers,” said Elizabeth Carpenter, vice president at Avalere. “When combined with new start-ups and other options created by the Affordable Care Act, the insurance market looks increasingly diverse.”
Read the report: http://bit.ly/1OzR8sv
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage
April 4th 2025This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
